|
1. |
Radiotherapy for Carcinoma of the BladderA Review |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 1-9
Zbigniew Petrovich,
Gabor Jozsef,
Luther Brady,
Preview
|
PDF (483KB)
|
|
摘要:
Carcinoma of the bladder (CaB) is a common and important tumor in North America and Western Europe. There has been a steady increase in the incidence of CaB during the past 25 years in both of these regions with a simultaneous decrease in the mortality rates. The decrease in mortality is primarily due to an earlier diagnosis and the availability of more effective therapeutic interventions resulting from major advances in surgery and a wide use of multimodality bladder preservation therapy.The use of radiotherapy in the management of muscle-invasive CaB has undergone a major evolution. External beam radiotherapy alone is used infrequently in carefully selected patients. The same applies to the use of preoperative irradiation. Brachytherapy alone or combined with external beam radiotherapy has been used successfully in Europe but is used infrequently in North America. External beam radiotherapy is an essential component of a multimodality therapy consisting of cytoreductive surgery via transurethral resection of a bladder tumor followed by a planned combination of radiotherapy and chemotherapy. The outcomes of this bladder preservation therapy are similar to those reported in a like patient population treated with radical cystectomy. The main benefit of conservatively treated patients is functioning bladder in about 50% of those receiving conservative therapy. Radiotherapy alone or in a combination with chemotherapy remains an important and effective palliative therapy for patients with recurrent and/or metastatic CaB.Current research efforts are directed toward a better identification of important pretreatment risk factors predicting failure thus helping in a more optimal selection of patients who would benefit most from radical cystectomy or from the application of bladder preservation therapy.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
2. |
Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S-Phase Analysis by Flow CytometryAn Eastern Cooperative Oncology Group Study (2192) |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 10-18
David Page,
Robert Gray,
D. Allred,
Lynn Dressler,
Alan Hatfield,
Silvana Martino,
Nicholas Robert,
William Wood,
Preview
|
PDF (90KB)
|
|
摘要:
Histologic evaluation and reporting of invasive breast cancer has effectively used Nottingham combined histologic grade (NCHG). This approach to predict outcome in invasive breast cancer has not been tested in multicenter cooperative trials. Histologic slides from selected breast cancer cases entered on node-negative Eastern Cooperative Oncology Group trials were assigned grades. Two pathologists evaluated cases for NCHG defined from differentiation, mitotic index, and nuclear grade. The study population consisted of separate samples from low- and high-risk strata, where low risk was estrogen receptor positive with a tumor size of less than 3 cm and high risk was estrogen receptor negative or tumor size greater than or equal to 3 cm. The rate of agreement was generally good, with 80% of cases classified the same for mitotic count and 76% of the cases classified the same for combined grade. There were no cases disagreeing from the lowest to the highest of the three categories. The median follow-up is 11.6 years, but for analysis of survival, this was truncated at 5 years. Mitotic index and combined grade as assessed by both pathologists showed significant associations with survival. High combined histologic grade was predictive for response to cyclophosphamide/methotrexate/5-fluorouracil (CMF) with survival differences at 5 years of 30% in the treated high-grade patients over the untreated patients. Overall, it is clear that pathologists can have close agreement in assignment of combined histologic grades, with highly significant prediction in univariate and borderline significance in multivariate analysis in prognostication of time to recurrence as well as survival. Thus, stratification used in these trials was highly prognostic as hoped, leaving a role for histologic grading in these relatively large tumors, more powerful than S-phase analysis in this series. In the subgroups of high-risk patients randomized between CMF and observation, there was a suggestion that the high-combined-grade group was predictive of treatment efficacy. We conclude that a combined histologic grade with defined criteria may be reliably assigned by practiced pathologists using readily available criteria, and that the measure may be of use in prognostication and prediction of therapeutic responsiveness when done in a technically ideal fashion.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
3. |
Use of Granulocyte Colony-Stimulating Factor After High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell TransplantationWhat Is the Optimal Timing? |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 19-25
Rasih Ener,
Sharon Meglathery,
Bulent Cuhaci,
David Topolsky,
Michael Styler,
Pamela Crilley,
Isadore Brodsky,
S. Benham Kahn,
Reginald King,
Preview
|
PDF (60KB)
|
|
摘要:
Administration of granulocyte colony-stimulating factor to patients undergoing high-dose chemotherapy and autologous peripheral blood stem cell transplantation accelerates neutrophil recovery and decreases hospitalization time. The optimal timing for granulocyte colony-stimulating factor infusion remains unknown. In this retrospective, case-controlled, two-armed study, we reviewed our experience at Hahnemann University Hospital to determine whether initiating granulocyte colony-stimulating factor infusions on posttransplant day 0 versus day 8 affects neutrophil recovery time, posttransplant discharge date, total hospital days after high-dose chemotherapy, and autologous peripheral blood stem cell transplantation. All patients hospitalized between 1994 and 1998 at Hahnemann University Hospital, Bone Marrow Transplantation Unit with breast cancer or non-Hodgkin’s lymphoma, who underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation and received granulocyte colony-stimulating factor either on posttransplant day 0 (16 patients) or day 8 (16 patients). The day 0 and day 8 groups had no statistically significant differences in age, sex, weight, height, body surface area, disease characteristics, pretransplant harvesting or conditioning regimens, or transplant CD34+cell counts. Our main outcome measure was the mean time to reach absolute neutrophil count greater than or equal to 0.5 × 109/l, the number of hospital days after transplant, and the total hospital days. The mean days to neutrophil recovery (10.56 versus 9.68,p= 0.48), posttransplant hospital days (13.62 versus 12.81,p= 0.39), and total hospital days (20.25 versus 20.25,p= 1.00) were not significantly different between day 8 and day 0 groups, respectively. No significant effects on neutrophil recovery time, posttransplant hospital days, or total hospital days were observed with the initial granulocyte colony-stimulating factor infusion on day 0 versus day 8 after transplant. Delayed administration may allow substantial cost savings (US$200 × 8 ≅ US$1,600 per patient) without affecting clinical outcome. More studies are needed to determine whether greater delay is feasible.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
4. |
Impact of Boost Technique on Outcome in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 26-32
Robert Frazier,
Larry Kestin,
Vijay Kini,
Alvaro Martinez,
Peter Chen,
Kathy Baglan,
Frank Vicini,
Preview
|
PDF (51KB)
|
|
摘要:
We reviewed our institution’s experience treating early-stage breast cancer patients with breast-conserving therapy (BCT) to determine the impact of boost technique on outcome. A total of 552 patients with stage I and II breast cancer were managed with BCT. All patients were treated with a partial mastectomy and radiation therapy (RT). RT consisted of 45 Gy to 50 Gy external beam irradiation to the whole breast followed by a boost to the tumor bed using either electrons (232 patients), photons (15 patients), or an interstitial implant (316 patients). Local control and cosmetic outcome was compared among three patient groups based on the type of boost used. Forty-one patients had a recurrence of cancer in the treated breast for 5-, 10-, and 13-year actuarial local recurrence rates of 2.8%, 7.5%, and 11.2%, respectively. There were no significant differences in the local recurrence rates or cosmetic outcome using electrons, photons, or an interstitial implant. On multivariate analysis, only young age and margin status were associated with local recurrence. Stage I and II breast cancer patients undergoing BCT can be effectively managed with electron, photon, or interstitial implant boost techniques. Long-term local control and cosmetic outcome are excellent regardless of which boost technique is used.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
5. |
Lumpectomy and Breast Irradiation for Breast Cancer Arising After Previous Radiotherapy for Hodgkin’s Disease or Lymphoma |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 33-34
Melvin Deutsch,
Kristina Gerszten,
William Bloomer,
Eli Avisar,
Preview
|
PDF (23KB)
|
|
摘要:
Twelve women treated with radiotherapy with or without chemotherapy for Hodgkin’s disease (11 patients) and non-Hodgkin’s lymphoma (1 patient) and in whom breast cancer subsequently developed 10 to 29 years later were treated with lumpectomy and breast irradiation, 5,000 cGy/25–30 fractions to the whole breast and 900 cGy to 1,000 cGy/5 boost to the operative area. Six also received adjuvant chemotherapy for breast cancer. Breast irradiation was well tolerated without any unusual acute or chronic sequelae. All women had a good to excellent cosmetic result. Ten women are alive and well 1 to 174 months (median: 46) from completion of breast irradiation. Two women died with distant metastasis but without local recurrence. Breast conservation therapy with radiotherapy is not contraindicated in the woman who has previously been treated with radiotherapy for Hodgkin’s disease or lymphoma.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
6. |
Merkel Cell Carcinoma Arising in the Head and NeckOptimizing Therapy |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 35-42
Brian Lawenda,
J. Thiringer,
Robert Foss,
Peter Johnstone,
Preview
|
PDF (401KB)
|
|
摘要:
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine dermal neoplasm. Because of the limited number of cases described in the literature (approximately 600 to date), statistically significant data regarding treatment are difficult to obtain. The majority of MCC cases affect the head and neck and are thought to be caused by the actinic damage associated with sun exposure. This study evaluates cases of head and neck MCC at Naval Medical Center San Diego (NMCSD) and compares the treatment regimens and outcomes from multiple institutions. This study is a retrospective outcomes analysis of all cases of head and neck MCC seen at NMCSD, between January 1, 1988 and June 30, 1998. The records of the NMCSD Tumor Registry were searched for patients with that diagnosis, and supplemental information was retrieved from the Radiation Oncology and Head & Neck Surgery Clinic charts. Eight of nine patients in this study were treated with either wide-local excision or Mohs microsurgery. The surgical margins were free of disease in all eight patients. One patient presented with distant metastatic disease, and two others were subsequently found to have nodal involvement. Subsequent therapy varied among the patients. Survey of the available literature revealed inconsistency in terms of which treatment regimens are optimal. Tumor resections are recommended by most groups to include a 2-cm to 3-cm tumor-free margin around the primary lesion when possible, but this is often difficult to achieve in the head and neck. Data, which do not reach statistical significance, suggest improved outcomes with tumor-free margins. Treatment of the regional draining lymph nodes is also recommended in most series. Prophylactic lymph node dissection or radiation therapy to the nodal chain may decrease local recurrence but does not consistently affect overall survival. Adjuvant chemotherapy is advocated by most groups in the treatment of metastatic disease because MCC is pathologically similar to small-cell lung carcinoma. However, no chemotherapy protocol has been shown to improve survival. Head and neck MCC is a rare and aggressive dermal tumor of neuroendocrine origin that requires multimodality therapy, including surgery, radiation therapy, and possibly adjuvant chemotherapy. Multiinstitutional studies are crucial to obtain sufficiently large populations to investigate and optimize therapy in this disease.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
7. |
Megestrol and Tamoxifen in Patients With Advanced Endometrial CancerAn Eastern Cooperative Oncology Group Study (E4882) |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 43-46
Kishan Pandya,
B. Yeap,
Louis Weiner,
James Krook,
John Erban,
Roger Schinella,
Thomas Davis,
Preview
|
PDF (38KB)
|
|
摘要:
To investigate the effect of adding tamoxifen to megestrol in the hormonal therapy for advanced endometrial cancer, 66 patients were entered in this study. Initially, 41 patients were randomized to either the standard progestin therapy of megestrol or to the combination of megestrol and tamoxifen between October 1982 and October 1984. The megestrol arm was terminated because of poor accrual and 25 patients were directly assigned to the combination arm. Among the 20 eligible cases on the megestrol arm, the response rate of 20% consisted of 1 complete response and 3 partial responses. The response rate on the megestrol plus tamoxifen arm was 19% with 1 (2%) complete response and 7 (17%) partial responses among 42 eligible cases. The median survival times were 12.0 months and 8.6 months, respectively. Only mild and moderate toxicities were observed on megestrol compared with more toxic complications observed on the combination of megestrol and tamoxifen, including a life-threatening case of pulmonary embolism. Although we could not carry out a comparative evaluation as intended, we conclude that the combination of megestrol and tamoxifen offers no clinical advantage over megestrol alone in the treatment of advanced endometrial carcinoma.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
8. |
Options for Investigative Postsurgical Therapy for Gastric Cancer, and Case Report of Using the Option for Combined Immunotherapy and Chemotherapy |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 47-51
Philipp Gerhardt,
Preview
|
PDF (40KB)
|
|
摘要:
The investigative therapy for a senior patient after radical subtotal gastroesophagectomy for regional lymph node and proximal esophagus metastasized adenocarcinoma (stage IIIA, T3, N1, M0) of the cardioesophageal junction is reported. The case has several unusual features: (1) the patient is the author and is not a physician; (2) in the absence of codified postsurgical treatment, he used his academic biomedical background, commercial associations, and international contacts to find and prioritize six clinically tested options for investigative postsurgical therapy; (3) after unsuccessful efforts to append ongoing clinical trials of new immunotherapies for breast adenocarcinoma (the first two therapy options), an innovative protocol was designed and gained allowance by the U.S. Food and Drug Administration for his use of combined nonspecific immunotherapy and chemotherapy based on extensive trials in South Korea that showed the synergistic effect of the two postsurgical therapies used together. A potent, new, nonspecific immunostimulant (DetoxPC) was injected subcutaneously in 10 diminishing doses during 105 weeks. Two standard chemotherapeutic drugs (5-fluorouracil and mitomycin-C) were injected intravenously in six equal doses during three weeks. Five years after the surgery, the patient enjoys good health without signs or symptoms of recurrence or metastasis. He discusses his perspectives on future clinical trials and on a patient actively pursuing investigative postsurgical therapy for a malignancy when otherwise poor survival is indicated.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
9. |
Absence of Major Peripheral Neuropathy in a Phase II Trial of Ifosfamide With Vinorelbine in Patients With Ovarian Cancer Previously Treated With Platinum and Paclitaxel |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 52-57
Gini Fleming,
Steven Waggoner,
Jacob Rotmensch,
Carole Langhauser,
Preview
|
PDF (45KB)
|
|
摘要:
Both ifosfamide and vinorelbine have been shown to produce responses in women with previously treated ovarian cancer. However, vinorelbine has been reported to cause severe neuropathy in patients previously treated with paclitaxel. We assessed a regimen consisting of ifosfamide 1.6 g/m2/d and vinorelbine 30 mg/m2/d for 3 days consecutively every 21 days. Because these doses resulted in severe neutropenia despite the use of granulocyte colony-stimulating factor, doses were reduced to a final level of ifosfamide 960 mg/m2/d and vinorelbine 20 mg/m2/d. Peripheral sensory neuropathy was evaluated by questionnaire. A total of 30 women were treated. All had previously been treated with both a platinum compound and paclitaxel. One partial response was observed among 23 patients with measurable disease, and two CA-125 responses were noted among seven patients without measurable disease. Severe progressive neurotoxicity was not observed. Despite the fact that almost half the patients had not been exposed to cyclophosphamide, this regimen produced few responses. Superior response rates have been reported with single-agent vinorelbine at doses that do not require growth factor support. With this dose and schedule, vinorelbine is reasonably safe therapy for patients who have received prior paclitaxel and who have have mild baseline sensory neuropathy.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
10. |
Chemotherapy for Acute Myelogenous Leukemia in the Elderly With Cytarabine, Mitoxantrone, and Granulocyte-Macrophage Colony-Stimulating Factor |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 24,
Issue 1,
2001,
Page 58-63
Matt Kalaycio,
Brad Pohlman,
Paul Elson,
Alan Lichtin,
Mohamad Hussein,
Barb Tripp,
and Steve Andresen,
Preview
|
PDF (46KB)
|
|
摘要:
Remission induction chemotherapy for acute myelogenous leukemia typically combines cytarabine with an anthracycline or anthracycline derivative. To date, no specific combination has emerged as more efficacious than any other. To reduce toxicity and shorten the duration of neutropenia, hematopoietic growth factors are often added to the chemotherapy regimen, especially in elderly patients. In all prospective, randomized, growth factor trials to date, daunorubicin has been the drug selected for combination with cytarabine. We hypothesized that mitoxantrone might be as efficacious in this patient population with perhaps less toxicity when combined with granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients older than age 55 years with a diagnosis of either de novo or secondary, untreated acute myelogenous leukemia were eligible for this clinical trial. Eligible patients were treated with cytarabine 100 mg/m2infused as a continuous infusion daily for 7 days and mitoxantrone 12 mg/m2bolus intravenously for the first 3 days of cytarabine. A second cycle of chemotherapy was administered on the fourteenth day of treatment if marrow aplasia was not achieved with the first cycle. Once aplasia was achieved, GM-CSF 250 &mgr;g/m2was given subcutaneously daily until neutrophil recovery. Those patients who achieved complete remission were treated with two cycles of intermediate-dose cytarabine (400 mg/m2daily for 5 days) and with GM-CSF as consolidation therapy. Of the 30 patients treated, the median age was 69 years (range: 55–76 years) and 18 patients were older than 65 years of age. Seven (23%) patients had secondary acute leukemia and 12 (40%) had poor-risk cytogenetics. Nineteen (63%) achieved a complete remission. Eleven patients were either refractory to treatment or died during their treatment. The toxicity encountered was no more than that reported in similar studies using daunorubicin in combination with cytarabine. Long-term survival was poor, with a median disease-free survival of only 8.1 months in patients who achieved complete remission. In this elderly population of patients with high-risk acute myelogenous leukemia, this combination of cytarabine, mitoxantrone, and GM-CSF resulted in an adequate remission rate with acceptable toxicity. Long-term survival, however, was poor and innovative treatment approaches to maintain remission are needed.
ISSN:0277-3732
出版商:OVID
年代:2001
数据来源: OVID
|
|